6533b835fe1ef96bd129e8fc
RESEARCH PRODUCT
Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors
David M. HymanSarat ChandarlapatyJoao LimaPeter KabosAnne C ArmstrongPaul RugmanKenji TamuraAndrew FoxleyHideaki BandoPhilippe L. BedardJosé BaselgaShaista SalimShannon N. WestinLillian M. SmythLeila AllandGaia SchiavonUdai BanerjiBenoit YouEmma DeanKathleen N. MooreHelen AmbroseAmit M. OzaJ. Alejandro Pérez-fidalgoMartin PassJustin P.o. Lindemannsubject
Cancer ResearchOncologymedia_common.quotation_subjectMolecular targetsEnvironmental ethicsArtAkt inhibitorPress conferenceHumanitiesmedia_commondescription
Abstract This abstract has been withheld from publication due to its inclusion in the AACR-NCI-EORTC Molecular Targets Conference 2015 Official Press Program. It will be posted online at the time of its presentation in a press conference or in a session: 10:00 AM ET Saturday, November 7. Citation Format: David M. Hyman, Lillian Smyth, Philippe L. Bedard, Amit Oza, Emma Dean, Anne Armstrong, Joao Lima, Hideaki Bando, Peter Kabos, J. Alejandro Perez-Fidalgo, Kathleen Moore, Shannon N. Westin, Benoit You, Sarat Chandarlapaty, Leila Alland, Helen Ambrose, Andrew Foxley, Justin Lindemann, Martin Pass, Paul Rugman, Shaista Salim, Gaia Schiavon, Kenji Tamura, Jose Baselga, Udai Banerji. AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B109.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-12-01 | Molecular Cancer Therapeutics |